Skip to content 
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois. more
| Time Frame | ABBV | Sector | S&P500 |
|---|---|---|---|
| 1-Week Return | 2.16% | 1.75% | 1.05% |
| 1-Month Return | -5.13% | -3.02% | -2.74% |
| 3-Month Return | 3.13% | 1.93% | 4.56% |
| 6-Month Return | 16.87% | 11.24% | 20.31% |
| 1-Year Return | 6.42% | 6.02% | 24.48% |
| 3-Year Return | 69.81% | 19.75% | 26.81% |
| 5-Year Return | 167.64% | 76.04% | 88.12% |
| 10-Year Return | 413.53% | 186.26% | 224.44% |
| Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
|---|---|---|---|---|---|---|
| Total Revenue | 33.27B | 45.80B | 56.20B | 58.05B | 54.32B | [{"date":"2019-12-31","value":57.3,"profit":true},{"date":"2020-12-31","value":78.9,"profit":true},{"date":"2021-12-31","value":96.8,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":93.56,"profit":true}] |
| Cost of Revenue | 7.44B | 15.39B | 17.45B | 17.41B | 8.78B | [{"date":"2019-12-31","value":42.64,"profit":true},{"date":"2020-12-31","value":88.2,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":99.82,"profit":true},{"date":"2023-12-31","value":50.33,"profit":true}] |
| Gross Profit | 25.83B | 30.42B | 38.75B | 40.64B | 45.54B | [{"date":"2019-12-31","value":56.72,"profit":true},{"date":"2020-12-31","value":66.79,"profit":true},{"date":"2021-12-31","value":85.1,"profit":true},{"date":"2022-12-31","value":89.24,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Gross Margin | 77.64% | 66.41% | 68.96% | 70.00% | 83.84% | [{"date":"2019-12-31","value":92.61,"profit":true},{"date":"2020-12-31","value":79.21,"profit":true},{"date":"2021-12-31","value":82.25,"profit":true},{"date":"2022-12-31","value":83.5,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Operating Expenses | 12.46B | 17.86B | 19.86B | 21.83B | 28.11B | [{"date":"2019-12-31","value":44.32,"profit":true},{"date":"2020-12-31","value":63.52,"profit":true},{"date":"2021-12-31","value":70.66,"profit":true},{"date":"2022-12-31","value":77.64,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
| Operating Income | 12.98B | 476.00M | 17.92B | 18.12B | 17.43B | [{"date":"2019-12-31","value":71.66,"profit":true},{"date":"2020-12-31","value":2.63,"profit":true},{"date":"2021-12-31","value":98.93,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":96.18,"profit":true}] |
| Total Non-Operating Income/Expense | (6.07B) | 642.00M | (5.90B) | (5.34B) | (12.86B) | [{"date":"2019-12-31","value":-944.86,"profit":false},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-918.54,"profit":false},{"date":"2022-12-31","value":-831.31,"profit":false},{"date":"2023-12-31","value":-2002.96,"profit":false}] |
| Pre-Tax Income | 8.43B | 3.40B | 12.99B | 13.48B | 6.25B | [{"date":"2019-12-31","value":62.52,"profit":true},{"date":"2020-12-31","value":25.21,"profit":true},{"date":"2021-12-31","value":96.38,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":46.38,"profit":true}] |
| Income Taxes | 544.00M | (1.22B) | 1.44B | 1.63B | 1.38B | [{"date":"2019-12-31","value":33.33,"profit":true},{"date":"2020-12-31","value":-75,"profit":false},{"date":"2021-12-31","value":88.24,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":84.38,"profit":true}] |
| Income After Taxes | 7.88B | 4.62B | 11.55B | 11.85B | 4.87B | [{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":39.02,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}] |
| Income From Continuous Operations | 7.88B | 4.62B | 11.55B | 11.85B | 4.87B | [{"date":"2019-12-31","value":66.54,"profit":true},{"date":"2020-12-31","value":39.02,"profit":true},{"date":"2021-12-31","value":97.5,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.14,"profit":true}] |
| Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
| Net Income | 7.88B | 4.62B | 11.54B | 11.84B | 4.86B | [{"date":"2019-12-31","value":66.59,"profit":true},{"date":"2020-12-31","value":39,"profit":true},{"date":"2021-12-31","value":97.52,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":41.09,"profit":true}] |
| EPS (Diluted) | 8.94 | 10.51 | 12.68 | 13.87 | 11.11 | [{"date":"2019-12-31","value":64.46,"profit":true},{"date":"2020-12-31","value":75.78,"profit":true},{"date":"2021-12-31","value":91.42,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":80.1,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
| ABBV | |
|---|---|
| Cash Ratio | 0.34 |
| Current Ratio | 0.87 |
| Quick Ratio | 0.76 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
| ABBV | |
|---|---|
| ROA (LTM) | 8.07% |
| ROE (LTM) | 35.20% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
| ABBV | |
|---|---|
| Debt Ratio Lower is generally better. Negative is bad. | 0.92 |
| Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.08 |
| Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 13.00 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
| ABBV | |
|---|---|
| Trailing PE | 62.56 |
| Forward PE | 14.58 |
| P/S (TTM) | 5.29 |
| P/B | 27.74 |
| Price/FCF | 66 |
| EV/R | 6.15 |
| EV/Ebitda | 19.45 |
| PEG | NM |
Dividend stocks have a proven record of stock market outperformance. For nearly 100 years, income-generating stocks on the S&P 500 have beaten non-payers. There has never been a decade when dividend stocks didn’t produce a positive return. And then we have the dividend royalty, companies that have raised their payouts the longest. These Dividend Kings have increased their dividends every year for 50 years or more without fail. Through wars, recessions and global pandemics, these businesses kept rewarding their investors for sticking by them. That doesn’t mean, however, their stocks will always go up. Economic factors and global events can temporarily slow business, causing investors to seek out faster growing stocks. But over time the Dividend Kings always rebound, explaining why they can still claim their thrones. The following are three royal dividend payers whose stocks are down 10% or more this year. You might want to consider buying these dividend stocks before they rebound once more.
Small-cap stocks tend to outperform their larger brethren over time. After several years of underperformance, it looked like the little guys were going to start winning again. Inflation was moderating and the Federal Reserve was hinting it would cut interest rates at least three times this year. Beginning last October, the performance of the Russell 2000 index of small-cap stocks started pulling away from that of the S&P 500 . But it wouldn’t last. Runaway government spending drove inflation higher and Fed chairman Jay Powell just intoned he no longer has “confidence” inflation is heading the right way. That means we won’t get interest rate cuts until at least December, according to some analysts. High interest rates are death to small businesses. Because they rely upon financing to fund their expansion, a rising rate environment absolutely kills the small business market. It’s why the Russell 2000 has been such a poor performer these past few years. It could also mean they will continue lagging in 2024.
AbbVie stock has slumped 10% off its record high in March and is facing increasingly steep competition for its biggest moneymaker, Humira.
WASHINGTON (dpa-AFX) - AbbVie Inc. (ABBV) Thursday announced positive results from SELECT-GCA Phase 3 of Upadacitinib 15 mg, once daily in combination with a 26-week steroid taper regimen in adult…
OSE has announced that its licence agreement with AbbVie has cleared antitrust review and has become effective. As previously noted, this is expected to support OSE''s runway extension into 2026, pa…
AbbVie Inc (ABBV) share price today is $167.8
Yes, Indians can buy shares of AbbVie Inc (ABBV) on Vested. To buy AbbVie Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ABBV stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of AbbVie Inc (ABBV) via the Vested app. You can start investing in AbbVie Inc (ABBV) with a minimum investment of $1.
You can invest in shares of AbbVie Inc (ABBV) via Vested in three simple steps:
The 52-week high price of AbbVie Inc (ABBV) is $181.2. The 52-week low price of AbbVie Inc (ABBV) is $125.85.
The price-to-earnings (P/E) ratio of AbbVie Inc (ABBV) is 61.69
The price-to-book (P/B) ratio of AbbVie Inc (ABBV) is 27.74
The dividend yield of AbbVie Inc (ABBV) is 3.66%
The market capitalization of AbbVie Inc (ABBV) is $297.11B
The stock symbol (or ticker) of AbbVie Inc is ABBV
Link copied 
